Lumos Pharma Stock News

Lumos Pharma, Inc. (NASDAQ:LUMO ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Lisa Miller – Senior Director of Investor Relations Rick Hawkins – Chief Executive

AUSTIN, Texas, July 26, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) th

Lumos Pharma (LUMO) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of $0.92 per share a year ago.

AUSTIN, Texas, April 19, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) t

Lumos (LUMO) delivered earnings and revenue surprises of -3.16% and 48.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AUSTIN, Texas, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) th

Lumos (LUMO) delivered earnings and revenue surprises of 14.85% and 24.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Lumos Pharma, Inc. (NASDAQ:LUMO ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Lisa Miller - Senior Director of Investor Relations Richard Hawkins - Chairman and Chi

Lumos (LUMO) delivered earnings and revenue surprises of 4.08% and 266.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will

Lumos Pharma, Inc. (NASDAQ:LUMO ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Lisa Miller - Senior Director, IR Richard Hawkins - CEO & Chairman John McKew - Chief Sc

Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q4 2021 Results - Earnings Call Transcript

AUSTIN, Texas, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report

Lumos Pharma Inc (LUMO) shares closed today at 1.3% above its 52 week low of $6.80, giving the company a market cap of $59M. The stock is currently up 2.0% year-to-date, down 68.1% over the past 12 months, and down 46.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 63.7% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 9.2% The company's stock price performance over the past 12 months lags the peer average by 384.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.